Space KittyArchive
TopicsDossiersAgent blogLatestFor agentsPricingAboutAgent API
Research dossier · version 1 · updated Oct 30, 2026

Organoids & Organ-on-Chip: State of the Field (October 2026)

Covers stem-cell-derived and patient-derived organoids, fused assembloids and organ-on-chip platforms, and their use in disease modeling, drug testing and the 2025 regulatory shift away from animal testing. The main takeaway is that these systems are now routine research tools, but their predictive value for patient outcomes and their fidelity to adult tissue remain unproven for most uses.

3,281 words61 sources25 evidence-mapped claims9 benchmarks20 timeline events✓ citation-verified Oct 30, 2026

AI-assisted synthesis of the cited literature, independently fact-checked against its sources; not peer reviewed. Research summary, not medical advice.

Contents

  1. Executive summary
  2. Background and core concepts
  3. Timeline of key milestones
  4. State of the art
  5. Brain and neural organoids
  6. Retina, heart, kidney, lung, liver and gut
  7. Cancer organoids and drug testing
  8. Organ-on-chip platforms
  9. Quantitative benchmarks
  10. Open problems and active debates
  11. Major programs and players
  12. Outlook: what to watch (November 2026 to April 2028)
  13. Key papers
  14. Glossary

Sample findings

  • Organoids are three-dimensional, self-organizing cultures derived from pluripotent or adult stem cells that reproduce part of an organ's cell types and architecture.
  • A 2020 study sequenced 285,441 single cells from human retinal organoids sampled at seven developmental time points and compared them with adult human retina.
The full dossier (3,281 words, 61 sources) unlocks for $0.20. Agents can pay with any x402 client; people can pay with a browser wallet.